An observational study in Alzheimer's Disease, Mild Cognitive Impairment and Parkinson's Disease, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Alzheimer Disease by Duke University — 4 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · Duke University.
Among the 15 studies in Alzheimer Disease by Duke University, this one is one of 3 that started in 2017, is one of 5 observational ones, and was the 8th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 15 studies in Alzheimer Disease by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 25–80 · Healthy volunteers
Duke University · Sites in United States
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 56 across the 10 interventional studies, 40 across the 5 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
2 of the studies in Alzheimer Disease by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
| NCT07425106Duke UniversityComparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3) | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Alzheimer Disease by Duke University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Using a multidisciplinary approach, this study aims to yield new insight into the vascular and structural pathophysiology of neurodegenerative disease. The investigators propose to develop and evaluate imaging biomarkers from OCT, OCTA, and UWF fundus photos to assess the structure and function of the retinal and choroidal microvasculature and structure in these individuals.
The investigators hypothesize that microvascular and structural network alterations in the retina and choroid may mirror and possibly precede changes in the cerebral microcirculation seen in these neurodegenerative diseases. Using advanced image analysis and machine learning techniques, the investigators aim to evaluate markers of reduced capillary blood flow and non-perfusion in the superficial retinal vascular plexus and choriocapillaris imaged using OCT and OCTA, in a resolution not previously possible, that would complement already established retinal structural markers and increase their sensitivity and specificity in the earlier detection of these neurodegenerative diseases.
This study looks to provide a proof of concept for retinal and choroidal imaging-based microvascular and structural biomarkers as an effective screening tool for neurodegenerative disease, particularly during in cognitive aging.
The protocol for this study was amended and the record was updated accordingly.
Neurology Clinics and the community.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
If two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.
Patients with (MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)
Device: Retinal and Choroidal Imaging
Controls will be recruited from the relatives/attendants of study participants or will be patients themselves and will not have a neurodegenerative disease diagnosis.
Device: Retinal and Choroidal Imaging
Non-invasive OCT, OCTA, and UWF fundus photography of retina
Change in ganglion cell-inner plexiform layer (GCIPL) thickness
Ganglion cell inner plexiform layer thickness as measured on optical coherence tomography scan of macula
Time frame: Baseline, 1 year
Change in retinal nerve fiber layer (RNFL) thickness
Retinal nerve fiber layer thickness as measured on optical coherence tomography scan of macula
Time frame: Baseline, 1 year
Change in central subfield thickness (CST)
Central subfield thickness as measured on optical coherence tomography scan of macula
Time frame: Baseline, 1 year
Change in choroidal vascularity index (CVI)
Choroidal vascularity index as measured using the COIN software in 1500 um area centered on the fovea
Time frame: Baseline, 1 year
Change in foveal avascular zone (FAZ) area
Foveal avascular zone area as measured in the superficial capillary plexus on 3mm optical coherence tomography angiography scan of the macula
Time frame: Baseline, 1 year
Change in average perfusion density (PD)
Average perfusion density as measured in the ETDRS 3mm and 6mm circle and rings on optical coherence tomography angiography scan of the macula
Time frame: Baseline, 1 year
Change in average vessel density (VD)
Average vessel density as measured in the ETDRS 3mm and 6mm circle and rings on optical coherence tomography angiography scan of the macula
Time frame: Baseline, 1 year
Change in average capillary perfusion density (CPD)
Capillary perfusion density as measured on peripapillary 4.5mm optical coherence tomography angiography scan
Time frame: Baseline, 1 year
Change in average capillary flux index (CFI)
Capillary flux index as measured on peripapillary 4.5mm optical coherence tomography angiography scan
Time frame: Baseline, 1 year
Change in retinal vessel tortuosity
Retinal vessel tortuosity measured on ultra-widefield scanning laser ophthalmoscopy image using VAMPIRE software
Time frame: Baseline, 1 year
Change in retinal vessel width gradient
Retinal vessel width gradient measured on ultra-widefield scanning laser ophthalmoscopy image using VAMPIRE software
Time frame: Baseline, 1 year
Change in retinal vessel fractal dimension
Retinal vessel fractal dimension measured on ultra-widefield scanning laser ophthalmoscopy image using VAMPIRE software
Time frame: Baseline, 1 year
Plan to share: No
Started Jul 2017 (actual). Primary completion is estimated for Dec 2026, 113 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 113 months is above that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.